Atrial Flutter

9

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Atrial Flutter is an early-stage landscape with 9 programs across 6 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Revance Therapeutics, Inc., Advanz Pharma. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Revance Therapeutics, Inc.

1 program

Advanz Pharma

1 program

Viking Therapeutics, Inc.

1 program

Bristol-Myers Squibb

1 program

Sanofi

1 program

Pipeline

Programs by Phase

Preclinical1

Antiarrhythmic Drug

Yonsei University

Phase 1

No programs

Phase 22

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Phase 31

Vernakalant

Advanz Pharma

Approved5

Ramipril

Viking Therapeutics, Inc.

Apixaban

Bristol-Myers Squibb

Dronedarone

Sanofi

Warfarin

Abbott

Pharmacological Cardioversion With Refralon

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Analysis

Trial Status

5

clinical trials

Completed3 · 60%

Unknown status2 · 40%

Clinical Trials

Trial Activity

Therapy of Atrial Flutter by Afib Ablation

Unknown status·UUniversity of Rostock·N/A·NCT02051621·100 enrolled

Half-normal Saline in Atrial Flutter Ablation

Completed·SSunnybrook Health Sciences Centre·N/A·NCT04001530·4 enrolled

Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter

Completed·National Medical Research Center for Cardiology, Ministry of Health of Russian Federation·Phase 4·NCT05445297·60 enrolled

Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT02002962·60 enrolled

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

Completed·AAdvanz Pharma·Phase 2/3·NCT00476112·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)